Collegium Pharmaceutical (COLL) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Collegium Pharmaceutical (COLL) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 45.2% versus a loss of 50.0%. Over five years, COLL leads with a +37.7% price change compared with -47.1% for SNDX. Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $768.2 million), about 1.0 times the size.
Collegium Pharmaceutical converts more of its revenue into profit, with a net margin of 8.1% versus -165.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | SNDX |
|---|---|---|
| Share price | $24.72 | $8.72 |
| Market cap | $768.18M | $785.05M |
| 1-day change | -1.94% | -4.49% |
| YTD return | -46.61% | -58.50% |
| 1-year return | -45.24% | -50.00% |
| 5-year return | +37.72% | -47.09% |
| P/E ratio (TTM) | 22.68 | — |
| Forward P/E | 3.49 | — |
| EPS (TTM) | $1.09 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $780.57M | $172.35M |
| Revenue growth (YoY) | +23.62% | +627.84% |
| Net income (latest FY) | $62.87M | $-285.42M |
| Gross margin | 59.35% | — |
| Operating margin | 23.01% | -158.45% |
| Net margin | 8.05% | -165.60% |
| 52-week high | $50.79 | $25.59 |
| 52-week low | $21.43 | $8.41 |
| Distance from 52-week high | -51.33% | -65.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.99% | +306.54% |
| Average volume | 754.45K | 2.63M |
| Shares outstanding | 31.08M | 90.03M |
| Employees | 423 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Collegium Pharmaceutical is more profitable, keeping 8.1 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
- Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +23.62%).
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
COLL vs SNDX FAQ
Which is bigger, Collegium Pharmaceutical or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $768.18M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or SNDX?
COLL returned -45.24% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.